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Primary systemic carnitine deficiency is caused by homozygous or compound heterozygous mutation in the SLC22A5 gene on
chromosome 5q31. The most common presentations are in infancy and early childhood with either metabolic decompensation
or cardiac and myopathic manifestations. We report a case of 9-year-old boy with dysmorphic appearance and hypertrophic
cardiomyopathy. Tandem MS spectrometry analysis was compatible with carnitine uptake defect (CUD). His sister had died
due to sudden infant death at 19 months. His second 4-year-old sister’s echocardiographic examination revealed hypertrophic
cardiomyopathy, also suffering from easy fatigability. Her tandem MS spectrometry analyses resulted in CUD. We sequenced all
the exons of the SLC22A5 gene encoding the high affinity carnitine transporter OCTN2 in the DNA. And one new mutation
(c.1427T>G → p.Leu476Arg) was found in the boy and his sister in homozygous form, leading to the synthesis of an altered protein
which causes CUD. The parent’s molecular diagnosis supported the carrier status. In order to explore the genetic background of
the patient’s dysmorphic appearance, an array-CGH analysis was performed that revealed nine copy number variations only. Here
we report a novel SLC22A5mutation with the novel hallmark of its association with dysmorphologic feature.
1. Introduction
Primary systemic carnitine deficiency (PCD) is caused by
homozygous or compound heterozygous mutation in the
SLC22A5 gene (MIM # 603377) on chromosome 5q31. PCD
is caused by defective activity of the OCTN2 carnitine
transporter, resulting in urinary carnitine wasting, low serum
carnitine levels, and decreased intracellular carnitine accu-
mulation. Carnitine is a water-soluble quaternary amine that
serves as an essential cofactor in transport of long-chain
fatty acids across the inner mitochondrial membrane for
subsequent beta oxidation. The lack of carnitine (due to
OCTN2 transporter deficiency) impairs the ability to use
fat as energy source during periods of fasting or stress
[1]. OCTN2 transporter deficiency is a lethal, autosomal
recessive disorder characterised by early childhood onset
cardiomyopathy, with or without weakness and hypotonia,
recurrent hypoglycemic hypoketotic seizures and/or coma,
failure to thrive, and extremely low plasma and tissue
carnitine concentrations (<%5 of normal) [2]. The clinical
manifestations of PCD can vary widely with respect to age
of onset, organ involvement, and severity of symptoms. The
most common presentations are in infancy and early child-
hood with either metabolic decompensation or cardiac and
myopathic manifestations, respectively. Half of the patients
typically present in later childhood around the age of 4
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Figure 1: (a) The boy, before carnitine treatment with significant mask face and dysmorphic findings (protruding large ears, hypertelorism,
epicanthal folds, swollen eyelids, narrow columella, and small nose). (b) The boy, 2 months after carnitine treatment.
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Figure 2: (a) Parasternal long-axis view depicting abnormally small left ventricular end-diastolic cavity, concentric left ventricular
hypertrophy (∗), and normal regional wall motion; (b) M-mode tracing across the interventricular septum demonstrating prominent
wall hypertrophy. LA: left atrium; LV: left ventricle; RV: right ventricle; Ao: aorta; IVSd: interventricular septum diastolic diameter; IVSs:
interventricular systolic diameter; LVIDd: left ventricular end-diastolic diameter; LVISd: left ventricular end systolic diameter; LVPWd: left
ventricular posterior wall thicknesses diastolic diameter; LVPWs: left ventricular posterior wall thicknesses systolic diameter; EF: ejection
fraction; FS: fractional shortening.
years (range: 1 year to 7 years) with dilated cardiomyopathy,
hypotonia, muscle weakness, and elevated creatine kinase
[3]. Following the finding of low plasma carnitine levels on
a screening assay, in a symptomatic individual, or in an
asymptomatic at-risk relative, the diagnosis of PCD can be
confirmed by SLC22A5 gene analysis. One molecular genetic
testing strategy is sequence analysis of SLC22A5. If biallelic
pathogenic variants are identified, the diagnosis of PCD is
confirmed [4].
2. Case Presentation
We report a case of 9-year-old boy referred to Pediatric
Genetics Clinic because of his dysmorphic appearance and
hypertrophic cardiomyopathy. He was suffering from easy
fatigability until he started walking. He was the first child of a
consanguineous (mother and fatherwere first degree cousins)
family. He was born at 35th gestational week, 1500 g and there
was not any pre- or postnatal complication. He could hold
his head at 3-4months, sat without being supported at 12th
month, and was able to walk at the age of 18months. On his
examination his weight and height were on 50th percentile.
His frontooccipital head measurement was below the −2 SD.
He had a long, mask face and protruding large ears, hyper-
telorism, epicanthal folds, swollen eyelids, narrow columella,
and small nose (Figure 1(a)). His shoulders were inclined for-
ward while sitting. His muscle strength was 5/5 for four limbs
and deep tendon reflexes were depressed. Creatine kinase
level was 150 u/L (30–200) and electromyography revealed a
myopathic pattern. TandemMS spectrometry analyses found
very low (0.92 uM) free carnitine (>3.8 uM normal) and low
(0.13 uM) C3 + C16 acylcarnitines (>2 normal). Carnitine
uptake defect (CUD) score was found 244, where 65 or
more is interpreted as severe carnitine deficiency. A transtho-
racic echocardiography was performed revealing abnormally
small left ventricular end-diastolic cavity, concentric left
ventricular hypertrophy with an ejection fraction of 82%,
and normal regional wall motion (Figure 2(a)). TheM-mode
image shows the increased septal and left ventricular poste-
rior wall thickness more than two standard deviations from
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Table 1: Detected CNVs, genomic position, and genes concerned based on hg19 (GRCh37).
Chromosome region Type of variation Genomic position Length OMIM genes involved (OMIM number)
2p21 Duplication 45,172,033–45,172,359 327 SIX3 (603714)
2q21.1 Duplication 131,280,135–131,280,852 718 CFC1 (605194)
6p25.3 Deletion 259,911–279,697 19,787 No genes
6q24.2 Duplication 144,328,772–144,328,954 184 PLAGL1 (603044)
8p23.1 Deletion 7,187,789–7,410,327 222,540 DEFB4A (602215), DEFB103A (606611),SPAG11 (606560)
10q11.22 Deletion 46,550,833–47,776,322 1,225,490
PTPN20A (610630), PTPN20B (610631),
SYT15 (608081), GPRIN2 (611240), PPYR1
(601790), ANXA8 (602396)
10q11.22 Deletion 48,879,347–49,262,377 383,031 No genes
14q32.33 Duplication 106,405,733–107,209,400 803,668 No genes
Xp22.33 Deletion 77,270–161,183 83,914 No genes
CNV = copy number variation.
the mean (Figure 2(b)). His second sister had died due to
sudden infant death at the age of 19months. His third 4-year-
old sister was also suffering from easy fatigability. She was
examinated by Pediatric Cardiology Clinic and diagnosed
as hypertrophic cardiomyopathy. Her tandem MS spectrom-
etry analyses resulted in CUD. Carnitine supplementation
(100mg/kg/daily) was started orally and both cases urinary
carnitine levels increased after treatment. During the follow-
up the dosage of carnitine was increased to 200mg/kg for
the boy. No adverse reactions were seen. Both of the siblings
showed clinical improvement (Figure 1(b)). CUD was not
detected on themother and fathers’ tandemMS spectrometry
analysis. Their echocardiographic evaluations were normal.
The boy and his sister’s molecular genetic test revealed
a homozygous SLC22A5 c.1427 T>G mutation leading to
an abnormal protein synthesis; therefore it supported the
diagnoses of OCTN2 carnitine transporter deficiency. We
sequenced all the 10 exons of the SLC22A5 gene encoding the
high affinity carnitine transporterOCTN2 both in the father’s
and the mother’s DNA using a previously described method
[5]. Compared to the reference sequence one mutation
(c.1427T>G → p.Leu476Arg) was found in heterozygous
form and three already known variants (rs 2631365, rs 274558,
and rs 274557) were detected in heterozygous form in the
mother’s DNA and homozygous form in the father’s DNA.
The protein coding mutation has not been described so far.
Software analysis (PolyPhen-2) predicted that the detected
mutation is possibly damaging.Molecular diagnosis supports
the carrier status.
An array-CGH analysis was performed on the DNA
extracted from whole blood of the proband using the Agilent
CytoChip ISCA SurePrint 8 × 60K oligo-array (Agilent
Technologies, USA) to explore the genetic background of the
patient’s dysmorphic appearance. Nine CNVs (copy number
variations) were detected in six chromosomes (Table 1); none
of them were proved to be pathogenic based on our in-
house database and the publicly available databases such
as DECIPHER (Database of Chromosomal Imbalance and
Phenotype in Humans using Ensembl Resources) [6], DGV
(the Database of Genomic Variants) [7], and Ensembl [8].
Moreover, none of them was found to be associated with
dysmorphic feature.
3. Discussion
PCD is an autosomal recessive disorder that impairs fatty
acid oxidation. It has a frequency of ranging from 1 : 40,000
to 1 : 120,000 newborns in different parts of the world [9–11]
and is possibly the second most frequent disorder of fatty
acid oxidation after medium chain acyl CoA dehydrogenase
deficiency [4]. In the heart, carnitine is essential for normal
fatty acid 𝛽-oxidation and even partial deficiency could lead
to organ dysfunction.
Cardiomyopathy is the most common clinical manifesta-
tion in children with PCD, which include dilated cardiomy-
opathy and hypertrophic cardiomyopathy [12]. In patients
with PCD dilated cardiomyopathy is more frequently found
[13] while cardiac hypertrophy can be seen in heterozygotes
for this condition [9]. Heterozygotes for PCD may have
mildly reduced plasma carnitine levels [14]. Over time,
heterozygotes develop benign cardiac hypertrophy and it is
unclear whether they have a higher incidence of cardiomy-
opathy or heart disease [9, 15]. Newborn screening with tan-
dem mass spectrometry is not routine in our country so our
patients are diagnosed late.The cases presented with cardinal
symptoms of easy fatigability. Hypertrophic cardiomyopathy
was detected by echocardiography. The mother and father
who determined heterozygous mutation of SLC22A5 were
screened by tandem mass and no carnitine deficiency was
revealed. Their echocardiographic screening was normal
as well. No association between genotype and phenotype
in PCD was found in previous studies [16]. Patients with
identical mutations can have different ages of onset and
different types of clinical presentations [17]. Even siblings
with the same mutation have different ages of onset and
different progressions of disease pointing to the presence
of clinical heterogeneity [18]. Affected children, between
the ages of 3months and 2 years, can present episodes of
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Table 2: Sequence analysis of the SLC22A5 gene.
Patient Genetested Genotype
Siblings
SLC22A5
c.285T>C homozygous sequence change
(p.Leu95Leu)
c.807A>G homozygous sequence change
(p.Leu269Leu)
c.824+13T>C homozygous sequence change
c.1427 T>G homozygous sequence change
(p.Leu476Arg)
Mother
c.285T>C heterozygous sequence change
(p.Leu95Leu)
c.807A>G heterozygous sequence change
(p.Leu269Leu)
c.824+13T>C heterozygous sequence change
c.1427 T>G heterozygous sequence change
(p.Leu476Arg)
Father
c.285T>C homozygous sequence change
(p.Leu95Leu)
c.807A>G homozygous sequence change
(p.Leu269Leu)
c.824+13T>C homozygous sequence change
c.1427 T>G heterozygous sequence change
(p.Leu476Arg)
metabolic decompensation triggered by fasting or common
illnesses such as upper respiratory tract infection or gastroen-
teritis. These episodes are characterized clinically by poor
feeding, irritability, lethargy, and hepatomegaly. Laboratory
evaluations usually reveal hypoketotic hypoglycemia (hypo-
glycemia with minimal or no ketones in urine), hyperam-
monemia, and elevated liver transaminases [4]. Both the boy
and his elder sister had skeletal and cardiac myopathic signs.
However, his little sister died due to sudden infant death. It
seems likely that her carnitine deficiencywasmore severe and
she had died with episode of hypoglycemia.
The boy had facial dysmorphia and microcephaly. The
chromosomal analysis of this case was normal and this case
could not be related to another dysmorphic syndrome. Kilic
et al. [18] reported one case CUD with facial dysmorphic
findings; however the dysmorphic status of that patient
clearly differs from that of our case. Meanwhile, dysmorphic
status cannot be explained with known function of carnitine
[19–23]. The array-CGH analysis of the proband revealed
known benign CNVs only, which are not affected by any
genes involved in the carnitine homeostasis and these CNVs
are not associated with dysmorphic feature.
More than 60 mutations in the SLC22A5 gene have been
found to cause primary carnitine deficiency. A total of four
geneticmutations in the SLC22A5 gene were identified in this
study (Table 2), which of one was described as novel.
Limitation of this study was that the supposed carnitine
uptake defect was not confirmed with the investigation of the
uptake by fibroblast.
4. Conclusion
A new homozygous mutation of c.1427T>G → p.Leu476Arg
was identified in these cases. Carnitine uptake defect is one of
the rare treatable etiologies of metabolic cardiomyopathies.
It should be suspected and searched for by measuring the
levels of free and total carnitine in plasma and urine from
such patients. The diagnosis of primary systemic carnitine
deficiency should be confirmed by identification of biallelic
pathogenic variants of SLC22A5 bymolecular genetic testing.
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